TheEdgeResearch
Home / Stocks / TXG

10x Genomics, Inc. (TXG)

NASDAQ Healthcare Medical - Healthcare Information Services
$56.99 ▼ -2.55%
Market Cap
$7.23B
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Beta
2.04
52-Wk Range
11.16-60.69
CEO
Serge Saxonov
Country
US
Currency
USD

10x Genomics, Inc. operates in the Medical - Healthcare Information Services industry of the Healthcare sector, headquartered in Pleasanton, CA, US. The stock last traded at $56.99, down 2.55% on the session, giving a market capitalisation of $7.23B. On trailing twelve-month figures it carries a trailing P/E of -96.59, a net margin of -12.2%. Its beta of 2.04 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-96.59
Price / Sales
11.73
Price / Book
8.97
EV / EBITDA
243.22
Gross margin
70.0%
Operating margin
-14.3%
Net margin
-12.2%
Return on equity
Debt / equity
0.10
Current ratio
5.69
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
1,178
IPO date
2019-09-12
Headquarters
Pleasanton, CA, US
About 10x Genomics, Inc.

Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.

Comparable companies

10x Genomics, Inc. is most often compared with the following Healthcare names:

CERTGRDNJANXNUVBOMCLOMDAPGNYSDGRSIONTDOC
More research on TXG
TXG technical analysis TXG TheEdge Score Compare against peers
Open full interactive analysis & DCF →